Pulmonx® Corp. announced that Zephyr Endobronchial Valve treats severe emphysema patients. This breakthrough technology offers bronchoscopic lung volume reduction without surgery and its associated risks.
The Zephyr Valve is the first minimally-invasive device which is useful for treating patients with severe emphysema, a progressive and life-threatening form of chronic obstructive pulmonary disease (COPD). It helps patients to breathe easier and enjoy more active lives.
US Food and Drug Administration (FDA) had approved the Zephyr® Endobronchial Valve System based on positive clinical data from the pivotal LIBERATE Study and two other multicenter randomised control trials.
Zephyr Valves play a key role in treating severe emphysema patients who consistently feel short of breath.
During a bronchoscopic procedure requiring no cutting or incisions, tiny Zephyr Valves are placed in the airways to occlude a diseased part of the lungs and reduce hyperinflation.
This helps the healthier parts of the lungs to expand and lifts pressure off the diaphragm, thereby decreasing shortness of breath and making breathing easier.
Patients most likely to benefit from Zephyr Valve treatment can be identified with assessment tools also offered by Pulmonx. Physicians use the Pulmonx Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform to help identify potential responders to Zephyr Valve treatment.
The Pulmonx Zephyr® Endobronchial Valves are implantable bronchial valves indicated for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation.
